← Back to Search

F18 Florbetapir (amyvid) cardiac PET/CT imaging for Cardiac Amyloidosis

Phase 4

Waitlist Available

Led By Chris Mueller, MD

Research Sponsored by Medical College of Wisconsin

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

Study Summary

This trial will test if a chemotherapy regimen can reduce the amount of amyloid protein in the heart of patients with AL amyloidosis.

Eligible Conditions

Cardiac Amyloidosis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Relative change in cardiac uptake of 18F florbetapir prior to chemotherapy and after six months of chemotherapy.

Secondary outcome measures

Cardiac response

Hematologic response

Patient related outcomes

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Patients with AL cardiac amyloidExperimental Treatment1 Intervention

Patients enrolled will be patients > 18 years of age with a clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis) with plans to undergo plasma cell directed chemotherapy.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor

609 Previous Clinical Trials

1,162,580 Total Patients Enrolled

Chris Mueller, MDPrincipal InvestigatorMedical College of Wisconsin

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA endorsed F18 Florbetapir (amyvid) for cardiac PET/CT imaging?

"Data collected from Phase 4 trials has provided evidence that F18 Florbetapir (amyvid) cardiac PET/CT imaging is a safe treatment, leading to its rating of 3 out of 3."

Answered by AI

Are there additional investigations utilizing F18 Florbetapir (amyvid) cardiac PET/CT imaging?

"Presently, there are 3 active tests assessing the efficacy of F18 Florbetapir (amyvid) cardiac PET/CT imaging. None have yet entered Phase 3. 8 medical sites across Ladera Ranch, California are conducting these investigations."

Answered by AI

Are there any open positions in this experiment for volunteers?

"Affirmative, the information provided on clinicaltrials.gov reveals that this medical trial is still recruiting subjects. This investigation was originally published in October 2020 and underwent its last revision in August 2021 with a target of 10 participants from 1 institution."

Answered by AI

To what extent is the trial pool populated?

"Affirmative. Clinicaltrials.gov reveals that this clinical trial, which was initially posted on October 1st 2020 is still actively enrolling participants. 10 volunteers are being sought after in a single location."

Answered by AI

Recent research and studies

Cell Death & DiseaseJournal

Cytotoxicity of Amyloidogenic Immunoglobulin Light Chains in Cell Culture

Sikkink, L A, and M Ramirez-Alvarado. 2010. “Cytotoxicity of Amyloidogenic Immunoglobulin Light Chains in Cell Culture”. Cell Death & Disease. Springer Science and Business Media LLC. doi:10.1038/cddis.2010.75.

Current Problems in CardiologyJournal

Current Trends in Diagnosis and Management of Cardiac Amyloidosis

Esplin, Brandt L., and Morie A. Gertz. 2013. “Current Trends in Diagnosis and Management of Cardiac Amyloidosis”. Current Problems in Cardiology. Elsevier BV. doi:10.1016/j.cpcardiol.2012.11.002.

Frontiers in Cardiovascular MedicineJournal

A Routine PET/CT Protocol with Streamlined Calculations for Assessing Cardiac Amyloidosis Using 18f-florbetapir

Osborne, Dustin R., Shelley N. Acuff, Alan Stuckey, and Jonathan S. Wall. 2015. “A Routine PET/CT Protocol with Streamlined Calculations for Assessing Cardiac Amyloidosis Using 18f-florbetapir”. Frontiers in Cardiovascular Medicine. Frontiers Media SA. doi:10.3389/fcvm.2015.00023.

New England Journal of MedicineJournal